{"entity":{"id":"torqur","kind":"company","name":"Torqur","aka":["Torqur AG","TORQUR"],"tldr":"Torqur is a Swiss company developing bimiralisib, a drug that blocks the PI3K and mTOR growth signals, as a tablet for cancer and as a skin gel for actinic keratosis, a sun-damage skin condition that can turn into skin cancer.","summary":"Torqur AG, based in Basel, was founded in 2021, according to the company, under the umbrella of Swiss Rockets AG, a Basel incubator, after acquiring the assets of Piqur Therapeutics AG, a University of Basel spin-off co-founded in 2011 by Vladimir Cmiljanovic to develop bimiralisib. Bimiralisib is a balanced pan-PI3K/mTOR inhibitor formulated for oral and topical use; the company states it has shown early clinical activity in several phase 1/2 studies. In August 2026 the European Commission granted oral bimiralisib orphan designation for thymic epithelial tumours, its first in a solid tumour, and the company also reports a collaboration with Lonza on the drug. Its only study registered on ClinicalTrials.gov, NCT06319794, a randomised phase 2 proof-of-concept study of topical bimiralisib gel in actinic keratosis, a precancerous skin lesion, was posted in March 2024 and is completed; it is not a cancer treatment trial.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.torqur.com/"},{"label":"Company page","url":"https://www.torqur.com/company"},{"label":"EU orphan designation for thymic epithelial tumours, August 2026","url":"https://www.torqur.com/news/torqur-receives-european-commission-orphan-drug-designation-for-bimiralisib-in-thymic-epithelial-tumours"},{"label":"ClinicalTrials.gov: phase 2 trial of topical bimiralisib in actinic keratosis (NCT06319794)","url":"https://clinicaltrials.gov/study/NCT06319794"}],"tags":[],"related":[],"cancers":["thymic-epithelial"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors"],"targets":["mtor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year from the company page, read on 29 October 2026. The earlier bimiralisib trials ran under Piqur Therapeutics and are not linked here. No bimiralisib drug record exists in the corpus. Financing not stated on the pages read. Included because the company describes itself as developing anti-cancer therapies; its registered trial is in a precancerous condition."],"hq":"Basel","country":"CH","companyType":"biotech","website":"https://www.torqur.com/","founded":2021,"stage":"startup","investors":[],"funding":[]},"route":"/companies/torqur/","neighbours":{"cancer":[{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"}],"target":[{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/"}]}}